These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29670334)

  • 1. Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas.
    Gong J; Yan J; Forscher C; Hendifar A
    Drug Des Devel Ther; 2018; 12():777-786. PubMed ID: 29670334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldoxorubicin for the treatment of soft tissue sarcoma.
    Sachdev E; Sachdev D; Mita M
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1175-1179. PubMed ID: 28846045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldoxorubicin in soft tissue sarcomas.
    Chamberlain FE; Jones RL; Chawla SP
    Future Oncol; 2019 May; 15(13):1429-1435. PubMed ID: 30873850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldoxorubicin therapy for the treatment of patients with advanced soft tissue sarcoma.
    Seetharam M; Kolla KR; Ganjoo KN
    Future Oncol; 2018 Oct; 14(23):2323-2333. PubMed ID: 29869517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.
    Chawla SP; Papai Z; Mukhametshina G; Sankhala K; Vasylyev L; Fedenko A; Khamly K; Ganjoo K; Nagarkar R; Wieland S; Levitt DJ
    JAMA Oncol; 2015 Dec; 1(9):1272-80. PubMed ID: 26378637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on aldoxorubicin (INNO-206) and its potential in the treatment of soft tissue sarcomas: evidence to date.
    Cranmer LD
    Onco Targets Ther; 2019; 12():2047-2062. PubMed ID: 30936721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.
    Chawla SP; Chua VS; Hendifar AF; Quon DV; Soman N; Sankhala KK; Wieland DS; Levitt DJ
    Cancer; 2015 Feb; 121(4):570-9. PubMed ID: 25312684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic study of aldoxorubicin in patients with solid tumors.
    Mita MM; Natale RB; Wolin EM; Laabs B; Dinh H; Wieland S; Levitt DJ; Mita AC
    Invest New Drugs; 2015 Apr; 33(2):341-8. PubMed ID: 25388939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma.
    Marrero L; Wyczechowska D; Musto AE; Wilk A; Vashistha H; Zapata A; Walker C; Velasco-Gonzalez C; Parsons C; Wieland S; Levitt D; Reiss K; Prakash O
    Neoplasia; 2014 Oct; 16(10):874-82. PubMed ID: 25379024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials.
    Kratz F
    Expert Opin Investig Drugs; 2007 Jun; 16(6):855-66. PubMed ID: 17501697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conjugate of Doxorubicin to Albumin-Binding Peptide Outperforms Aldoxorubicin.
    Yousefpour P; Ahn L; Tewksbury J; Saha S; Costa SA; Bellucci JJ; Li X; Chilkoti A
    Small; 2019 Mar; 15(12):e1804452. PubMed ID: 30756483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma.
    Martin-Liberal J; Pérez E; García Del Muro X
    Expert Opin Investig Drugs; 2019 Jan; 28(1):39-50. PubMed ID: 30513001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic Therapy for Advanced Soft Tissue Sarcoma.
    Sheng JY; Movva S
    Surg Clin North Am; 2016 Oct; 96(5):1141-56. PubMed ID: 27542647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy.
    Davis EJ; Chugh R
    Drug Des Devel Ther; 2017; 11():3579-3587. PubMed ID: 29263653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group.
    Verweij J; Lee SM; Ruka W; Buesa J; Coleman R; van Hoessel R; Seynaeve C; di Paola ED; van Glabbeke M; Tonelli D; Judson IR
    J Clin Oncol; 2000 May; 18(10):2081-6. PubMed ID: 10811673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
    Bramwell VH; Morris D; Ernst DS; Hings I; Blackstein M; Venner PM; Ette EI; Harding MW; Waxman A; Demetri GD
    Clin Cancer Res; 2002 Feb; 8(2):383-93. PubMed ID: 11839653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J; Emons G; Pinski J; Schally AV
    Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
    Abu Ajaj K; Graeser R; Kratz F
    Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
    Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
    Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.